Keyword: Rigel Pharmaceuticals
The erroneous claim was up on Rigel’s website for more than 24 hours before a spike in the company’s stock raised awareness of the mistake.
Rigel Pharma—just days away from hearing from the FDA on its first marketing application for lead drug fostamatinib—has reported disappointing phase 2 data in a follow-up indication.
Rigel Pharmaceuticals fell about 35% in early trading on news that a second Phase III trial for its fostamatinib missed the primary endpoint.
California biotech Rigel Pharmaceuticals has posted positive new late-stage data for its experimental thrombocytopenia treatment and says it is eyeing a 2017 submission to the FDA.